From: Early diagnosis of breast and ovarian cancers by body fluids circulating tumor-derived exosomes
Exosomal marker | Cancer type | Clinical value | References |
---|---|---|---|
let-7, miR-200 | OC SKOV-3 and OVCAR-3 cell lines | The exosomal let-7 miRNA expression was significantly greater in SKOV-3 (high invasive cell line) compared with OVCAR-3 (low invasive cell line) The expression of miR-200 family was only identified in OVCAR-3 cell-derived exosomes | [84] |
miR-21, miR-23b, miR-29a | OC effusion supernatants | High expression all three exosomal microRNAs was associated with poor survival | [85] |
miR-21, miR-141, miR-200a, miR-200b, miR-200c, miR-203, miR-205, miR-214 | OC patients serum | Overexpression exosomal microRNAs in different stages of OC patients Exosomal microRNAs were significantly lower in benign OC patients and negative in control cases | [52] |
miR-373, miR-200a, miR-200b, miR-200c | OC patients serum | Overexpression all four exosomal microRNAs in OC patients The levels of miR-200a, miR-200b, and miR-200c distinguished between malignant and benign OC The increased levels of miR-200c and miR-200b were associated with CA125 values and shorter overall survival | [53] |
miR-99a-5p | OC patients serum | MiR-99a-5p significantly elevated in OC patients compared to benign patients and healthy individuals | [54] |
miR-30a-5p | OC patients urine | High levels of miR-30a-5p in OC patients | [58] |
EpCAM, CD24 | OC patients ascite | High levels of EpCAM and CD24 in OC patients | [50] |
EpCAM, CD24, CA-125 | OC patients plasma | High levels of EpCAM, CD24, and CA-125 in OC patients | [51] |
EpCAM, CD24, CA-125, HER2, EGFR, FRα, CD9, CD63 | OC patients plasma | This panel distinguished early and late stage OC and discriminated patient groups from benign subjects | [59] |
CD24, L1CAM, ADAM10, EMMPRIN | OC patients ascites | Malignant ascites-derived exosomes contained tumor progression related proteins CD24, L1CAM, ADAM10, and, EMMPRIN. | [57] |
TGF-β1, MAGE3/6 | OC patients plasma | TGF-β1, MAGE3/6 distinguished OC patients from benign group and healthy controls | [55] |
Claudin-4 | OC patients plasma | High levels of Claudin-4 in OC patients | [56] |
CD24, EpCAM | OC patients ascite | EpCAM and CD24 were enriched in exosomes from ascites and pleural effusions | [68] |
BC patients pleural effusions and serum | EpCAM was absent from BC patients serum | ||
miR-373, miR-101 | BC patients serum | High levels of miR-373 and miR-101 in BC patients compared to benign patients and healthy individuals Higher levels of miR-373 in more aggressive tumors (triple-negative and hormone receptor-negative BCs) | [63] |
miR-105 | BC patients serum | Overexpression of miR-105 in BC cells was associated with high risk of metastasis | [64] |
miR-21, miR-1246 | BC patients plasma | High levels of miR-21, miR-1246 in BC samples compared to healthy subjects | [65] |
miR-223-3p | BC patients plasma | Higher levels of miR-223-3p in IDC group compared to DCIS patients and healthy controls | [66] |
miR-27a, miR-27b, miR-335, miR-365, miR-376c, miR-382, miR-422a, miR-433, miR-628 | BC patients plasma | miRNAs 27b, 335, 376c, 382, and 433 were upregulated in TNBC patients miRNAs 27a, 27b, 365, and 628 were upregulated in HER2-positive BC patients miR-422a was downregulated in HER2-positive BC patients | [74] |
lncRNA HOTAIR | BC patients plasma | Positive correlation between the exosomal HOTAIR and HER2-positive BC patients | [75] |
CD82 | BC patients plasma | High levels of CD82 in BC exosomes is associated with high risk of metastasis | [69] |
Del-1 | BC patients plasma | Del-1 significantly elevated in BC patients compared to healthy controls | [70] |
GPC1 | BC patients serum | High levels of GPC1 in 75% of BC patients compared to healthy individuals | [71] |
Survivin-2B | BC patients serum | Survivin significantly elevated in BC patients compared to healthy controls | [73] |
GSTP1 | BC patients serum | GSTP1 significantly elevated in chemo-resistant BC patients compared to chemo-sensitivite BC group | [77] |